• Login
  • Register
Nairametrics
  • Home
  • Exclusives
    • Recapitalization
      • Access Holdings Offer
      • Fidelity Bank Offer
      • GTCO Offer
      • Zenith Bank Offer
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Nairalytics
  • Economy
    • Business News
    • Budget
    • Public Debt
    • Tax
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Public Offer & Right Issues
      • Stock Market News
    • Fixed Income
    • Funds Management
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Market Views
    • Op-Eds
    • Research Analysis
  • Home
  • Exclusives
    • Recapitalization
      • Access Holdings Offer
      • Fidelity Bank Offer
      • GTCO Offer
      • Zenith Bank Offer
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Nairalytics
  • Economy
    • Business News
    • Budget
    • Public Debt
    • Tax
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Public Offer & Right Issues
      • Stock Market News
    • Fixed Income
    • Funds Management
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Market Views
    • Op-Eds
    • Research Analysis
Nairametrics
Home Business News

NCDC warns Nigerians against use of chloroquine for COVID-19

Chike Olisah by Chike Olisah
March 26, 2020
in Business News, Socio Economic
NCDC warns Nigerians against use of chloroquine for COVID-19, COVID-19: Three Dead As Nigeria Records 505 New Cases, Nigeria records 1,149 new Covid-19 cases, highest in 6 months

Dr Chikwe Ihekweazu, DG NCDC

Share on FacebookShare on TwitterShare on Linkedin

The Federal Government of Nigeria has insisted that chloroquine has not been approved as a cure for the coronavirus disease.

The warning came from the Director-General of the Nigerian Centre for Disease Control (NCDC), Dr Chikwe Ihekweazu while reacting to recent media reports that suggested that chloroquine could protect people from the coronavirus disease or treat patients that are already infected with the disease.

 Ihekweazu said, ”Nigerians should please remember that the use of chloroquine and its derivatives for the management of COVID-19 disease has not been validated and approved by the World Health Organization (WHO).

MoreStories

Kuwait implements ‘Kuwaitisation’ employment policy barring foreign nationals from oil jobs

Kuwait introduces immigration reforms with longer residency, clearer visa rules 

January 22, 2026
Hilda Baci, GWR

Hilda Baci earns third Guinness World Record for world’s largest rice serving 

January 21, 2026

“There have been promising results by researchers but until then, the drug is not approved for use for COVID-19 treatment.

“Nigerians should know that self-medication can cause harm and lead to death.

“Do not misuse drugs. We understand these are challenging times, and Nigerians may be worried, but the Federal Ministry of Health, through the NCDC is doing everything it can to continue to ensure the safety and health security of every Nigerian.

“Chloroquine and hydroxychloroquine have not been licensed to treat COVID-19 related symptoms or prevent infection,” he said.

[READ MORE: COVID-19: Tesla to produce ventilators to curb COVID-19 spread)

NCDC warns Nigerians against use of chloroquine for COVID-19

The NCDC boss pointed out that clinical trials were still in progress to test chloroquine and hydroxychloroquine as an agent in the treatment of coronavirus or to prevent its infection and have not been completed yet. So as a result, the safety and effectiveness of this medicine to treat or prevent coronavirus have not been ascertained yet.

He also said that until the WHO, have clear, definitive evidence that these treatments were safe and effective for the treatment of COVID-19, it should not be misused. In addition to responding to the outbreak, NCDC has begun a communications campaign to debunk misinformation and provide Nigerians with facts to protect their health.

It was reported some days back that the National Agency for Food and Drug Administration and Control (NAFDAC) approved the production of Chloroquine for clinical trials.

However, the Director-General of the agency, Mojisola Adeyeye, pointed out that NAFDAC is not approving Chloroquine for the treatment of COVID-19 but only for clinical trials to find treatment for the virus

Meanwhile, the breakdown of COVID-19 cases by states in the country shows that Lagos State still has the highest number of confirmed cases in the country with 32 cases, followed by Abuja with 10 cases, Ogun State three, and Ekiti, Oyo Edo, Bauchi Osun and Rivers have one case each.

Most of the cases reported are travellers who returned from those high-risk countries. Other cases are people who have come in contact with infected people.


Add Nairametrics on Google News
Follow us for Breaking News and Market Intelligence.
Tags: CoronavirusCovid-19Dr. Chikwe IhekweazuMojisola AdeyeyeNAFDACNCDCNigerian Centre for Disease Control
Chike Olisah

Chike Olisah

Chike was a banker with over 11 years experience in retail and commercial banking, risk management, treasury portfolio management and relationship management. He also acquired some experience in financial management and do have some special interest in investment analysis and personal finance. He had stints with financial institutions like the former Intercontinental Bank and Fidelity Bank.

Next Post
COVID-19: Teams, Slack make more money as firms adopt remote working

COVID-19: Teams, Slack make more money as firms adopt remote working

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

rabafast

access bank
nairametrics
first bank









DUNS

Follow us on social media:

  • HOME
  • ABOUT NAIRAMETRICS
  • CONTACT US
  • DISCLAIMER
  • ADs DISCLAIMER
  • COPYRIGHT INFRINGEMENT

© 2026 Nairametrics

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Social Media Auto Publish Powered By : XYZScripts.com
No Result
View All Result
  • Home
  • Exclusives
    • Recapitalization
      • Access Holdings Offer
      • Fidelity Bank Offer
      • GTCO Offer
      • Zenith Bank Offer
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Nairalytics
  • Economy
    • Business News
    • Budget
    • Public Debt
    • Tax
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Public Offer & Right Issues
      • Stock Market News
    • Fixed Income
    • Funds Management
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Market Views
    • Op-Eds
    • Research Analysis
  • Login
  • Sign Up

© 2026 Nairametrics